Seven long-acting microsphere preparations are on the way in the Nuggets 10 billion inhalation preparation market

From the successful transformation of a health care product company to a pharmaceutical company, Joincare Group has been remarkable along the way
.
It owns two listed companies, Joincare and Livzon Pharmaceuticals, focusing on innovative drugs and high-barrier complex preparations, and has created two 1 billion yuan single products
.
4 new products of the group's inhalation preparation pipeline are expected to be mass-produced within this year, striving towards the leading goal; 7 varieties of microsphere preparation pipeline are under research, and triptorelin microspheres are the first domestically produced; they have won the first domestically produced recombinant HCG, more than 10 varieties Biopharmaceuticals are on the way
.
At the beginning of the year, Joincare released its 2021 annual performance forecast.
It is expected that the net profit attributable to shareholders of listed companies in 2021 will be 1.
255 billion yuan to 1.
367 billion yuan, a year-on-year increase of 12% to 22%
.
The main reason for the change in performance is that during the reporting period, the sales growth rate of the chemical preparations segment was obvious, and the sales in key advantageous areas such as respiratory, digestive tract, gonadotropin, and spirituality achieved sustained and rapid year-on-year growth.
In addition, the profitability and proportion of high-end specialty APIs in the API segment were steady.
The improvement ensures the steady growth of the company's overall performance
.
Joincare Pharmaceutical Group was founded on December 18, 1992 and listed on the Shanghai Stock Exchange in June 2001.
It is an innovative and scientific research-based comprehensive pharmaceutical group
.
It owns two large listed companies, Joincare and Livzon Pharmaceuticals, and its subsidiaries include Livzon Group, Livzon mAb, Haibin Pharmaceutical, Taitai Pharmaceutical, Fangyu Health,
etc.
After years of development, the company's products cover the fields of biological drugs, prescription drug preparations, APIs, health products, OTC, diagnostic reagents and equipment, etc.
A certain market advantage has been formed in the field
.
The company adheres to R&D and innovation as the driving force, focuses on the R&D of innovative drugs and high-barrier complex preparations, and has formed a relatively clear product R&D pipeline around the product line layout in the fields of antimicrobial, anti-tumor, gonadotropin, digestion, nerve and respiration
.
In recent years, the company has continued to increase investment in research and development, focusing on the construction of technology platforms such as inhalation drug delivery, antibody technology, sustained-release microspheres and lipo-microemulsion, and continuously improving its research and development competitiveness
.
In the first three quarters of 2021, the company's research and development expenses were 959 million yuan, a year-on-year increase of 37.
85%
.
Nuggets 10 billion inhalation preparation market, 4 major explosive products are expected to be launched After the centralized procurement of health yuan inhalation preparations, the volume of inhalation preparations has accelerated significantly, which will make a huge contribution to the company's 2021 annual performance
.
In recent years, Joincare has increased investment in the research and development of inhalation preparations mainly for the treatment of respiratory diseases, and the product line of inhalation preparations has been enriched day by day, laying a solid foundation for the strategic goal of building a "domestic inhalation preparation leading enterprise"
.
At present, 4 varieties (7 product specifications) of the company's respiratory inhalation preparations have been approved for marketing, including levalbuterol hydrochloride atomized inhalation solution, compound ipratropium bromide solution for inhalation, ipratropium bromide solution for inhalation and Budesonide suspension for inhalation
.
Among them, levalbuterol hydrochloride atomized inhalation solution entered the national medical insurance catalog through negotiation, and achieved rapid coverage and sales growth after the implementation of medical insurance in March 2021; the remaining 3 varieties were successfully selected for the fifth batch of national centralized procurement, with significant volume and accelerated commercialization.

.
According to data from Minet.
com, in 2020, the sales of terminal anti-asthma and chronic obstructive pulmonary drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 20 billion yuan, of which the market for inhaled preparations The share has reached as high as 70%, and it is showing an upward trend year by year
.
Sales of terminal anti-asthma and COPD drugs in Chinese public medical institutions (unit: RMB 10,000) Source: Minet Occupy, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim and other three pharmaceutical companies occupy nearly 60% of the market share, and there is huge room for local companies to replace the market
.
With the continuous advancement of the pipeline, the product line of Joincare inhalation preparations will usher in an intensive harvest period.
Moterol inhalation solution is expected to be approved for marketing in 2022, of which tobramycin is expected to become my country's first inhalation antibiotic
.
Joincare is expected to be approved to market inhalants in 2022, with two 1 billion explosive products in hand! 7 high-end microsphere preparations Livzon Group's existing products cover the field of gonadotropins, digestive tract, spiritual, anti-infective and traditional Chinese medicine preparations, etc.
Each therapeutic field has its own representative products, such as injections Leuprolide acetate microspheres, ilaprazole series products, fluvoxamine maleate tablets, voriconazole for injection, antiviral particles,
etc.
After years of market cultivation, Livzon Group's innovative drug ilaprazole series products and leuprolide acetate microspheres for injection of high-barrier complex preparations have become large varieties of 1 billion yuan
.
Among them, the sales revenue of leuprolide acetate microspheres for injection in 2020 was 1.
176 billion yuan, a year-on-year increase of 27.
01%; the sales revenue in the first half of 2021 was 818 million yuan, a year-on-year increase of 52.
49%; the sales revenue of ilaprazole series in 2020 was 1.
766 billion yuan Yuan, an increase of 81.
20% year-on-year; sales revenue in the first half of 2021 was 1.
531 billion yuan, a year-on-year increase of 130.
64%
.
At present, Livzon Group is focusing on the research and development of innovative drugs and high-barrier complex preparations
.
On February 24, Livzon Group announced that the Class 1 new drug LZ001 tablet was approved for clinical trials
.
LZ001 tablet is a new generation of tyrosine kinase inhibitor, which is intended for the treatment of advanced solid tumors.
It is the company's first class 1 new drug approved for clinical use this year
.
According to data from Minet.
com, in 2020, the sales of terminal protein kinase inhibitors in Chinese public medical institutions will exceed 26 billion yuan, a year-on-year increase of 30%
.
The company's microsphere pipeline is also continuously advancing, and there are 7 main products under development
.
Among them, triptorelin acetate microspheres for injection (1-month sustained-release) have submitted a marketing application; leuprolide acetate microspheres for injection (3-month sustained-release) have completed Phase I clinical; azole microspheres (1-month sustained-release) have been carried out in Phase I clinical trials
.
Livzon Group is developing microsphere products It is worth mentioning that Livzon Group's microspheres of triptorelin acetate for injection are expected to become the first domestically produced microspheres
.
At present, only 2 triptorelin microsphere preparations have been approved for import in China, which are from France Ipsen and Ferring Pharmaceuticals
.
According to data from Minet.
com, the sales of terminal triptorelin microsphere preparations in Chinese public medical institutions will exceed 1 billion yuan in 2020, and its sales will exceed 600 million yuan in the first half of 2021, a year-on-year increase of 41.
34%
.
Won the first domestic recombinant HCG, and more than 10 biological drugs are on the way.
Livzon Monoc Established in July
.
The company focuses on the fields of oncology, immune diseases and assisted reproduction.
The products under development include recombinant proteins, antibodies, vaccines, and CAR-T cell therapy
.
Among them, recombinant human chorionic gonadotropin for injection has been approved for marketing, recombinant humanized anti-human IL-6R monoclonal antibody injection (tocilizumab injection) has been declared for marketing, and more than 10 varieties are in other stages
.
Recombinant human chorionic gonadotropin for injection is an assisted reproductive drug, and it is the first domestic imitation of Merck Serono recombinant human chorionic gonadotropin (Aize)
.
According to data from Minet.
com, in 2020, the sales of recombinant human chorionic gonadotropin in public medical institutions in China will be close to 60 million yuan
.
It is worth mentioning that this product will form a synergistic effect with Livzon Group's listed leuprolide microspheres for injection, urinary follicle stimulating hormone for injection, urinary gonadotropin for injection, chorionic gonadotropin for injection and other assisted reproductive drugs.

.
Recombinant humanized anti-human IL-6R monoclonal antibody injection is a biosimilar of Roche's Tocilizumab.
Bio-Thera and Livzon have successively submitted marketing applications to compete for the first domestic tocilizumab Biosimilars
.
According to Roche's financial report, the sales revenue of tocilizumab injection (Yamiro) in 2021 will be 3.
562 billion Swiss francs (about 3.
899 billion US dollars, according to the average exchange rate in 2021)
.
Among more than 10 varieties in different stages of research and development, recombinant anti-human IL-17A/F humanized monoclonal antibody injection has launched Phase II clinical trials; recombinant tumor enzyme-specific interferon α-2b Fc fusion protein, recombinant human follicle-stimulating Hormone injection has launched Phase I clinical trials; recombinant humanized anti-PD-1 monoclonal antibody for injection has launched Phase Ib/II clinical trials; Sequentially strengthened Phase III clinical trials of recombinant novel coronavirus fusion protein vaccine (V-01) The interim key data has been obtained, and it is ready to apply for a conditional listing
.
Data source: Minet database, company announcement